IPCAVD 003

Status:Completed
Phase:I
Principal Investigator(s):Lindsey Baden, MD
Objective:To determine the safety of and immune response to an adenovirus serotype HIV vaccine in HIV uninfected adults.last updated March 30, 2021
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Placebo, Randomized
Arms and Assigned Interventions
DescriptionParticipants will receive the Ad26.ENVA.01 (rAd26) vaccine at baseline.
Mode of DeliveryIntermuscular
ARMsExperimental
Results: Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
Official Code: NCT01103687
Related Publications:
Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine t
Trial Sponsors: NIAID
Start Date
End Date
July 31, 2010
September 30, 2012
Enrollment:24
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women